Concepedia

Ivacaftor withdrawal syndrome in cystic fibrosis patients with the G551D mutation

Aaron Trimble, Scott H. Donaldson

Journal of Cystic Fibrosis · 2017 · 66 citations · 11 references

DOI

Concepts

References

11

A CFTR Potentiator in Patients with Cystic Fibrosis and the <i>G551D</i> Mutation

Bonnie W. Ramsey, Jane C. Davies, Noel G. McElvaney et al. · New England Journal of Medicine · 2011 · 2.2K citations · Full text

, , +8

Effect of VX-770 in Persons with Cystic Fibrosis and the G551D- <i>CFTR</i> Mutation

Frank J. Accurso, Steven M. Rowe, John P. Clancy et al. · New England Journal of Medicine · 2010 · 802 citations · Full text

, , +12

Efficacy and Safety of Ivacaftor in Patients Aged 6 to 11 Years with Cystic Fibrosis with a <i>G551D</i> Mutation

Jane C. Davies, Claire Wainwright, Gerard J. Canny et al. · American Journal of Respiratory and Critical Care Medicine · 2013 · 506 citations · Full text

, , +14

Results of a phase IIa study of VX-809, an investigational CFTR corrector compound, in subjects with cystic fibrosis homozygous for the <i>F508del-CFTR</i> mutation

John P. Clancy, Steven M. Rowe, Frank J. Accurso et al. · Thorax · 2011 · 496 citations · Full text

, , +16

Calcium and cAMP activate different chloride channels in the apical membrane of normal and cystic fibrosis epithelia.

Matthew P. Anderson, Michael J. Welsh · Proceedings of the National Academy of Sciences · 1991 · 373 citations

, , +17